The CDC ICD-10-CM browser confirms R13.10 as the unspecified entry, and AAPC's reference places it under the R13 range
Further, much of the published research has yet to be translated into the English language [1]
Compounding pharmacies make customized medicines for individual patients, and under section 503A of the Food, Drug, and Cosmetic Act, a pharmacy can compound from a bulk substance only if that substance has an official quality monograph, is a component of an FDA-approved drug, or has been formally added to an approved bulks list. BPC-157 qualifies on none of those counts, which is why the FDA placed it in Category 2 of its 503A bulk-substance review in September of 2023
This allows targeted treatment in applications related to the brain and its function
That said, GI issues have many causes and BPC-157 is not a substitute for a proper diagnosis
very satisfied